Clinical Trials Directory

Trials / Unknown

UnknownNCT05128331

sPERMIdine supplemenTation on Metabolic, Neuronal and Cardiovascular Response to Exercise TRAINING

The Effect of sPERMIdine supplemenTation on the Metabolic, Neuronal and Cardiovascular Response to Exercise TRAINING in Patients With Heart Failure With Preserved Ejection Fraction

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
30 (estimated)
Sponsor
University Medicine Greifswald · Academic / Other
Sex
All
Age
50 Years – 100 Years
Healthy volunteers
Not accepted

Summary

This study explores whether spermidine supplementation improves the metabolic, neurological-cognitive and cardiovascular response to structured exercise training in patients with heart failure with preserved ejection fraction. The investigators aim to show that a faster adaptation to exercise may improve long term adherence to a more active lifestyle.

Detailed description

Heart failure with preserved ejection fraction is the largest unmet need in medicine. Exercise training is a pivotal lifestyle intervention which has been shown to have beneficial effects with regards to metabolic, neurological-cognitive and cardiovascular outcomes in these patients. Yet, not every patients responds equally fast to an exercise training intervention. This trial explores whether the supplementation of spermidine can increase the response to a structured aerobic exercise training. The investigators will recruit 30 patients who will either receive a spermidine supplement or a placebo. The study participants are invited for a first follow-up visit after four weeks. The exercise intervention starts at week 5 and continues for 12 weeks. Hence, overall there are three visits (baseline, week four and week twelve).

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTspermidineLifedietary supplement that is made of natural wheat germ extract with high spermidine content
DIETARY_SUPPLEMENTPlacebodietary supplement that is made of cellulose.

Timeline

Start date
2021-08-11
Primary completion
2023-12-31
Completion
2023-12-31
First posted
2021-11-22
Last updated
2022-05-25

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT05128331. Inclusion in this directory is not an endorsement.